Article Text
Abstract
Objectives Interval colorectal cancer (CRC) after colonoscopy may affect effectiveness and cost-effectiveness of screening programmes. We aimed to investigate whether and how faecal haemoglobin concentration (FHbC) of faecal immunochemical testing (FIT) affected the risk prediction of interval cancer (IC) caused by inadequate colonoscopy quality in a FIT-based population screening programme.
Design From 2004 to 2009, 29 969 subjects underwent complete colonoscopy after positive FIT in the Taiwanese Nationwide CRC Screening Program. The IC rate was traced until the end of 2012. The incidence of IC was calculated in relation to patient characteristics, endoscopy-related factors (such adenoma detection rate (ADR)) and FHbC. Poisson regression analysis was performed to assess the potential risk factors for colonoscopy IC.
Results One hundred and sixty-two ICs developed after an index colonoscopy and the estimated incidence was 1.14 per 1000 person-years of observation for the entire cohort. Increased risk of IC was most remarkable in the uptake of colonoscopy in settings with ADR lower than 15% (adjusted relative risk (aRR)=3.09, 95% CI 1.55 to 6.18) and then higher FHbC (μg Hb/g faeces) (100–149: aRR=2.55, 95% CI 1.52 to 4.29, ≥150: aRR=2.74, 95% CI 1.84 to 4.09) with adjustment for older age and colorectal neoplasm detected at baseline colonoscopy. Similar findings were observed for subjects with negative index colonoscopy.
Conclusions Colonoscopy ICs arising from FIT-based population screening programmes were mainly influenced by inadequate colonoscopy quality and independently predicted by FHbC that is associated with a priori chance of advanced neoplasm. This finding is helpful for future modification of screening logistics based on FHbC.
- COLORECTAL CANCER SCREENING
- COLORECTAL CANCER
- SCREENING
- COLORECTAL NEOPLASIA
- COLONOSCOPY
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Footnotes
The preliminary results of this study were presented during the Research Forum, Digestive Disease Week 2014 (May 6, 2014, Chicago, Illinois, USA; Abstract # 1896191).
Contributors Conception and design of the study: SY-HC, H-MC, Y-CL, S-LC, SL-SC, AM-FY, JC-YF; generation, collection, assembly, analysis and/or interpretation of data: H-MC, S-LC, SL-SC, AM-FY, SY-HC, D-CC and JC-YF; drafting or revision of the manuscript: SY-HC and H-MC; critical revision of the manuscript for important intellectual content; approval of the final version of the manuscript: all authors; administrative, technical or material support: S-LC, SL-SC, H-MC, AM-FY, SY-HC, JC-YF, D-CC, Y-CL, M-SW, C-KC, W-FH and S-TC; study supervision: H-MC; H-MC had the final responsibility for the decision to submit for publication.
Funding This study was supported by the Health Promotion Administration, Ministry of Health and Welfare (A1011119 and A1021227), and Ministry of Science and Technology (MOST 102-2314-B-182-028-MY3). The funding source had no role in study design, data collection, analysis, or interpretation, report writing, or the decision to submit this paper for publication.
Competing interests None declared.
Ethics approval This study was approved by the Health Promotion Administration of the Ministry of Health and Welfare prior to data retrieval and analysis.
Provenance and peer review Not commissioned; externally peer reviewed.